Advertisement
YOU ARE HERE: LAT HomeCollectionsRegeneron Pharmaceuticals Inc
IN THE NEWS

Regeneron Pharmaceuticals Inc

FEATURED ARTICLES
BUSINESS
January 26, 1993
Regeneron Pharmaceuticals Inc. said it has been awarded a patent covering the gene for a biotechnology-based protein that Regeneron and Amgen Inc. are developing to treat neurological diseases. The patent also was awarded to the Max Planck Institute, which has licensed the technology exclusively to Regeneron. Regeneron, a fledgling biotechnology company based in Tarrytown, N. Y.
ARTICLES BY DATE
BUSINESS
January 26, 1993
Regeneron Pharmaceuticals Inc. said it has been awarded a patent covering the gene for a biotechnology-based protein that Regeneron and Amgen Inc. are developing to treat neurological diseases. The patent also was awarded to the Max Planck Institute, which has licensed the technology exclusively to Regeneron. Regeneron, a fledgling biotechnology company based in Tarrytown, N. Y.
Advertisement
BUSINESS
February 11, 1992 | JAMES F. PELTZ, TIMES STAFF WRITER
Regeneron Pharmaceuticals Inc., a fledgling biotechnology company that's partially owned by Amgen Inc. in Thousand Oaks, has taken a few more baby steps on its long journey toward producing marketable drugs. Regeneron, based in Tarrytown, N.Y., is trying to develop drugs that would treat Parkinson's disease, Alzheimer's disease and other neurological ailments.
BUSINESS
February 11, 1992 | JAMES F. PELTZ, TIMES STAFF WRITER
Regeneron Pharmaceuticals Inc., a fledgling biotechnology company that's partially owned by Amgen Inc. in Thousand Oaks, has taken a few more baby steps on its long journey toward producing marketable drugs. Regeneron, based in Tarrytown, N.Y., is trying to develop drugs that would treat Parkinson's disease, Alzheimer's disease and other neurological ailments.
BUSINESS
April 16, 1991 | JAMES F. PELTZ, TIMES STAFF WRITER
Regeneron Pharmaceuticals Inc., which caused a splash on Wall Street when it went public recently, hopes one day to be the next Amgen Inc.--that is, the next blockbuster biotechnology company. And Amgen hopes Regeneron becomes the next Amgen. That's because Amgen, based in Thousand Oaks, is a major partner in the effort by 3-year-old Regeneron to develop and market biotechnology-based drugs that would combat Parkinson's disease, Alzheimer's disease and other neurological ailments.
BUSINESS
September 11, 1990
Amgen Inc., a Thousand Oaks biotechnology concern, said it entered into a multiyear pact with Regeneron Pharmaceuticals Inc. to develop certain proteins, called neurotropic factors, that might be developed into biotechnology drugs that could help treat various neurological disorders. Under the deal, the companies will form a partnership to commercialize the factors, which might be used for treating Alzheimer's and Parkinson's diseases.
BUSINESS
July 11, 1995 | Compiled by Jack Searles
Amgen Inc., the Thousand Oaks biotechnology firm, says encouraging test results have been obtained for a drug it is co-developing with a New York firm to treat amyotrophic lateral sclerosis, or Lou Gehrig's disease. Results have been encouraging enough to begin a third-phase trial, said Amgen and its partner in the project, Regeneron Pharmaceuticals Inc. of Tarrytown, N.Y.
BUSINESS
April 21, 2005 | From Bloomberg News
Biogen Idec Inc.'s former chief scientific officer, Nabil Hanna, agreed to pay $372,000 to settle allegations he used confidential information to profit on a stock trade, the Securities and Exchange Commission said Wednesday. The SEC alleged that Hanna, 61, bought shares of Regeneron Pharmaceuticals Inc. before the company disclosed in September 2003 that it would develop a potential cancer treatment with Aventis.
BUSINESS
July 13, 2002 | From Bloomberg News
Amgen Inc., the world's largest biotechnology company, won U.S. antitrust clearance Friday to complete its $9.6-billion purchase of Immunex Corp., maker of a leading rheumatoid arthritis drug. Amgen and Immunex received Federal Trade Commission approval for the takeover after the companies agreed to grant patent licenses to allow development of two rival anti-arthritis drugs to address FTC concerns that the acquisition would hurt competition and lead to higher drug prices.
BUSINESS
January 11, 1997 | BARRY STAVRO, TIMES STAFF WRITER
Amgen Inc. and its partner Regeneron Pharmaceuticals Inc. struck out Friday in their long effort to develop a biotechnology drug to treat Lou Gehrig's disease--announcing that their test drug BDNF is not effective against the fatal nerve disease. Amgen had hoped the test drug would be among its first successful new products in six years, but BDNF was unable to significantly improve the condition of 1,000 patients suffering from Lou Gehrig's disease, the two firms reported.
BUSINESS
April 16, 1991 | JAMES F. PELTZ, TIMES STAFF WRITER
Regeneron Pharmaceuticals Inc., which caused a splash on Wall Street when it went public recently, hopes one day to be the next Amgen Inc.--that is, the next blockbuster biotechnology company. And Amgen hopes Regeneron becomes the next Amgen. That's because Amgen, based in Thousand Oaks, is a major partner in the effort by 3-year-old Regeneron to develop and market biotechnology-based drugs that would combat Parkinson's disease, Alzheimer's disease and other neurological ailments.
BUSINESS
January 12, 1993 | JAMES F. PELTZ, TIMES STAFF WRITER
Amgen Inc., the biotechnology giant in Thousand Oaks, is collaborating with a fledgling Northern California company on developing new drug treatments for blood-related disorders. The four-year pact announced Monday between Amgen and Sugen Inc., based in Redwood City, calls for the companies to jointly develop and market any drugs they can commercialize, and to then share the profits. Amgen also purchased a 10% equity stake in privately held Sugen.
BUSINESS
July 19, 1994 | From Reuters
Synergen Inc. said Monday that its lead product, Antril, has failed in clinical trials for treatment of the blood infection sepsis and that it will cut its staff in half, an announcement that sparked a steep drop in the company's stock price. Synergen's stock lost nearly half its value in heavy trading after the announcement and closed down $4.375 at $4.50 on the Nasdaq, where it was the second-most-active issue in afternoon trading.
Los Angeles Times Articles
|